文献类型：期刊文献

英文题名：Effect of chitooligosaccharides with a specific degree of polymerization on multiple targets in T2DM mice

作者：You, Jiangshan[1];Zhao, Mengyao[1,3];Chen, Shumin[1];Jiang, Lihua[1,3];Gao, Shuhong[1];Yin, Hao[2];Zhao, Liming[1,3]

机构：[1]East China Univ Sci & Technol, Sch Biotechnol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China;[2]Shanghai Changzheng Hosp, Organ Transplant Ctr, Shanghai 200003, Peoples R China;[3]Shanghai Collaborat Innovat Ctr Biomfg Technol SC, Shanghai 200237, Peoples R China

年份：2022

卷号：9

期号：1

外文期刊名：BIORESOURCES AND BIOPROCESSING

收录：;EI(收录号：20224513087730);WOS:【SCI-EXPANDED(收录号:WOS:000849655000001)】；

基金：This study was endorsed by the National Key R&D Program of China (Grant number 2019YFD0901805, 2019YFD090180302), the National Natural Science Foundation for Young Scientists of China (No. 31801668), the Open Project Funding of the State Key Laboratory of Bioreactor Engineering, ECUST (ZDXM2019), the Fundamental Research Funds for the Central Universities [Grant number 22221818014], and the 111 Project B18022).

语种：英文

外文关键词：Chitooligosaccharides; Diabetes mellitus; Insulin resistance; Hypoglycemic effect

摘要：Chitooligosaccharides (COS) are found naturally in the ocean and present a variety of physiological activities, of which hypoglycemic action has attracted considerable research attention. This study aimed to assess the therapeutic effect of COS on mice suffering from type 2 diabetes mellitus (T2DM). COS effectively reduced blood glucose and blood lipid levels and improved glucose tolerance. Furthermore, COS revealed strong inhibitory activity against alpha-glucosidase, reducing postprandial blood glucose levels. Molecular docking data showed that COS might interact with surrounding amino acids to form a complex and decrease alpha-glucosidase activity. Additionally, COS enhanced insulin signal transduction and glycogen synthesis while restricting gluconeogenesis in the liver and muscles, reducing insulin resistance (IR) as a result. Moreover, COS effectively protected and restored islet cell function to increase insulin secretion. These results indicated that COS exhibited a significant hypoglycemic effect with multi-target participation. Therefore, COS may serve as a new preventive or therapeutic drug for diabetes to alleviate metabolic syndrome.